CALIXAR team will be present at the online BIO Asia - Taiwan event, from July 21 to 25, 2021 to discuss about commercial and scientific opportunities linked to our activities.
CALIXAR is a biotech company specialized in the identification and isolation of functional membrane therapeutic targets and antigens (GPCRs, Ion channels, Transporters, …). The company is currently investing in the extension of its pipeline of highly druggable membrane protein targets and native antigens. Within the next few years, CALIXAR will be able to offer to Pharma companies native and functional therapeutic targets validated and in a ready-to-discovery format.
CALIXAR wants to become a leader in the early discovery segment of drug development based on complex therapeutic targets (membrane proteins), a market predicted to be worth € 70 bn by 2025.
About BIO Asia – Taiwan event
Jointly organized by the global Biotechnology Innovation Organization (BIO) and the Taiwan Bio Industry Organization (Taiwan BIO) the BIO Asia – Taiwan International Conference and Exhibition was held for the first time in 2019. This year BIO Asia – Taiwan 2021 (online), brings together biotechnology and pharmaceutical executives and investors from North America, Europe and Asia to explore business opportunities with Taiwan’s emerging biotech sector with a unique format of online and live settings.
For more information and meet us: BIO Asia - Taiwan
